Concept and clinical evaluation of carrier-mediated anticancer agents.
about
The big picture on nanomedicine: the state of investigational and approved nanomedicine productsLiposomes as nanomedical devicesAn efficient targeted drug delivery through apotransferrin loaded nanoparticlesA novel magnetic nanoparticle drug carrier for enhanced cancer chemotherapyA new theranostic system based on gold nanocages and phase-change materials with unique features for photoacoustic imaging and controlled release.Potential applications and human biosafety of nanomaterials used in nanomedicineEngineering of hetero-functional gold nanorods for the in vivo molecular targeting of breast cancer cells.Nanomedicine: towards development of patient-friendly drug-delivery systems for oncological applicationsInterpatient pharmacokinetic and pharmacodynamic variability of carrier-mediated anticancer agents.Pharmacokinetics and efficacy of PEGylated liposomal doxorubicin in an intracranial model of breast cancer.Cancer cell invasion: treatment and monitoring opportunities in nanomedicine.Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors.Effects of tumor microenvironment heterogeneity on nanoparticle disposition and efficacy in breast cancer tumor models.Evaluation of the efficiency of tumor and tissue delivery of carrier-mediated agents (CMA) and small molecule (SM) agents in mice using a novel pharmacokinetic (PK) metric: relative distribution index over time (RDI-OT).Cholesterol-tethered platinum II-based supramolecular nanoparticle increases antitumor efficacy and reduces nephrotoxicityThe effects of nanoparticle drug loading on the pharmacokinetics of anticancer agents.Mechanism-based model characterizing bidirectional interaction between PEGylated liposomal CKD-602 (S-CKD602) and monocytes in cancer patientsMarqibo® (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine.Nanomedicine in chemoradiation.A simple way to enhance Doxil® therapy: drug release from liposomes at the tumor site by amphiphilic block copolymer.Translational studies of phenotypic probes for the mononuclear phagocyte system and liposomal pharmacology.In vivo toxicity studies of europium hydroxide nanorods in miceDesign and fabrication of magnetic nanoparticles for targeted drug delivery and imaging.Top-down particle fabrication: control of size and shape for diagnostic imaging and drug delivery.Enhancement of the efficacy of therapeutic proteins by formulation with PEGylated liposomes; a case of FVIII, FVIIa and G-CSF.The use of PEGylated liposomes in the development of drug delivery applications for the treatment of hemophilia.Nanomaterials: applications in cancer imaging and therapy.Pegylated liposomal doxorubicin: a review of its use in metastatic breast cancer, ovarian cancer, multiple myeloma and AIDS-related Kaposi's sarcoma.Challenges in development of nanoparticle-based therapeutics.Optimizing Druggability through Liposomal Formulations: New Approaches to an Old Concept.Nanoparticles as delivery carriers for anticancer prodrugs.Therapeutic nanoparticles in clinics and under clinical evaluation.In vivo studies of nanostructure-based photosensitizers for photodynamic cancer therapy.Formulation and physiologic factors affecting the pharmacology of carrier-mediated anticancer agents.Challenges in preclinical to clinical translation for anticancer carrier-mediated agents.Magnetically Targeted Nanocapsules for PAA-Cisplatin-Conjugated Cores in PVA/SPIO Shells via Surfactant-Free Emulsion for Reduced Nephrotoxicity and Enhanced Lung Cancer Therapy.ZEB1 knockdown mediated using polypeptide cationic micelles inhibits metastasis and effects sensitization to a chemotherapeutic drug for cancer therapy.Intestinal absorption of fluorescently labeled nanoparticles.In vitro and in vivo evaluation of lipofufol, a new triple stealth liposomal formulation of modulated 5-fu: impact on efficacy and toxicity.Complex effects of tumor microenvironment on the tumor disposition of carrier-mediated agents.
P2860
Q27021817-1A1C60FA-4FD0-4170-9A9A-20FBDF9642E0Q28088315-39A1F836-8B40-476B-B903-C33616F0C327Q28476276-CCBCEEA8-4BD9-44A0-92C1-5715BF5333C4Q28484262-94FE1216-B817-4267-93AA-EF6F041005E4Q30468699-1D6A2298-7D4E-4AC5-B226-5283B39551D0Q32944368-99ED47E1-414A-4DFD-9191-3AA0B3C41401Q34127424-A6D158AC-527E-4D45-B433-A45EB5F66315Q34259986-E80B1689-384C-4FC8-B768-7ACF2AC0E2F7Q34265621-CFFFC527-CE97-4547-ADD5-B929D86DE03FQ34708283-E4BF672B-93F0-4F09-9ADB-0DEA355343B7Q35093966-76401439-EA3A-43D3-82F5-C9101E7324C4Q35100986-454E1278-EE02-46D2-B508-6909345DAB32Q36047366-CB3C0F52-15CF-44B1-A89A-9D45CFD81D26Q36071814-3ACA1C48-C910-4899-9259-73DABC17AC20Q36094353-D94F39E4-F651-4239-8E56-B179CE5D81EEQ36126057-754C5F79-3317-4E19-8C63-B79B9A35944DQ36344679-6D14D697-B9D1-42E9-A0EB-6548579D79B0Q36629939-618D726F-06CC-4A63-9FAF-C9C2C0513CE2Q36838995-8661D065-B188-44C8-92AB-A89721A8F04FQ36867763-34B5457B-9651-4D79-A2C2-D90E95149212Q37331793-8F5A912B-686D-40EE-B9CB-D50AB18483C2Q37388332-7B92F98D-372B-49D2-8C53-576806574C76Q37631874-C4ACFE60-2CD7-46DB-B084-BE921FC5997CQ37668337-54F269F3-3395-48C6-9472-45C22B541DA0Q37679949-F24779F3-AF5C-45A2-B6EF-B541F740BEBCQ37790614-6A47A9C1-8718-45CF-A51C-A49F20A48685Q37857064-04D079A7-29CA-4B03-BD1F-05D3ED6CE153Q37964713-CDB70A9B-70FB-4CC0-8981-897070CD6D2AQ37992525-0D93744E-0C29-4C6B-916F-FB0A3B7CC552Q37999793-49B290ED-6144-49FA-9774-17B83D5FD4B8Q38002956-ECA521D4-4BA6-4293-AFAC-74895059D7B3Q38087986-C34E284A-A33F-4532-AC39-3DC8AC9D69FFQ38244010-4C501595-4C01-43AE-AC76-F3D34577BA37Q38546964-BEA41A8F-F382-4500-87A5-1E3E178EC0FCQ38723333-CD85CB4C-ADCC-4382-84E1-969A8DA3FD15Q38912446-87C67C09-AF8A-45C6-8F77-2C3C3EA0B5BAQ38974682-D1ACFFA6-F8C9-489E-97BF-DC9942019143Q39027218-B737E375-1D20-4C34-BD0F-C8A42C4FDC79Q39198848-ACBAF6EB-9FCD-4304-8155-B8D68281DA17Q39458957-3CFA049E-532F-4A46-88E5-A14FF09B59E5
P2860
Concept and clinical evaluation of carrier-mediated anticancer agents.
description
2008 nî lūn-bûn
@nan
2008 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի մարտին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Concept and clinical evaluation of carrier-mediated anticancer agents.
@ast
Concept and clinical evaluation of carrier-mediated anticancer agents.
@en
Concept and clinical evaluation of carrier-mediated anticancer agents.
@nl
type
label
Concept and clinical evaluation of carrier-mediated anticancer agents.
@ast
Concept and clinical evaluation of carrier-mediated anticancer agents.
@en
Concept and clinical evaluation of carrier-mediated anticancer agents.
@nl
prefLabel
Concept and clinical evaluation of carrier-mediated anticancer agents.
@ast
Concept and clinical evaluation of carrier-mediated anticancer agents.
@en
Concept and clinical evaluation of carrier-mediated anticancer agents.
@nl
P1433
P1476
Concept and clinical evaluation of carrier-mediated anticancer agents.
@en
P2093
William C Zamboni
P304
P356
10.1634/THEONCOLOGIST.2007-0180
P577
2008-03-01T00:00:00Z